论文部分内容阅读
为了探讨ｃｅｒｂＢ２、ｐ５３、ＣＥＡ及ＰＣＮＡ在非小细胞肺癌中的表达及其与临床的关系，采用免疫组化ＬＳＡＢ方法，对２３例非小细胞肺癌进行检测，结果显示，在腺癌的ｐ５３，ＣＥＡ，ｃｅｒｂＢ２表达阳性率分别为４４％，６６％，７７％，鳞癌的表达阳性率分别为２１％，２８％，３５％；鳞癌的阳性表达率明显低于腺癌。ｃｅｒｂＢ２、ｐ５３、ＣＥＡ阳性表达与淋巴结转移无关（Ｐ＞０．０５），只有ＰＣＮＡ阳性表达与淋巴结转移有关，在有淋巴结转移和无淋巴结转移的非小细胞肺癌的患者中，ＰＣＮＡ表达的阳性率分别为２５％和９％，淋巴结转移患者的ＰＣＮＡ表达阳性率明显高于无淋巴结转移者（Ｐ＜０．０５）。ｐ５３、ＣＥＡ的表达与生存期有关，生存６个月以下和１２个月的患者的ｐ５３表达阳性率分别为５０％，２０％（Ｐ＜０．０５），ＣＥＡ的阳性率分别为６０％，４０％（Ｐ＜０．０５），从而提示ｐ５３和ＣＥＡ表达阳性率越高，患者生存期越短，预后差。
To investigate the expression of cerbB2, p53, CEA, and PCNA in non-small cell lung cancer and its relationship with the clinic, 23 cases of non-small cell lung cancer were detected by immunohistochemical LSAB method. The positive rates of p53, CEA and cerbB2 expression were 44%, 66%, and 77%, respectively. The positive rates of squamous cell carcinoma were 21%, 28%, and 35%, respectively; the positive rate of squamous cell carcinoma was significantly lower. In adenocarcinoma. The positive expression of c-erbB-2, p53 and CEA was not related to lymph node metastasis (P>0.05). Only PCNA positive expression was associated with lymph node metastasis. PCNA was found in patients with non-small cell lung cancer with lymph node metastasis and no lymph node metastasis. The positive rates of expression were 25% and 9% respectively, and the positive rate of PCNA expression in patients with lymph node metastasis was significantly higher than those without lymph node metastasis (P<0.05). The expression of p53 and CEA was related to the survival period. The positive rate of p53 expression in patients who survived 6 months and 12 months was 50% and 20% respectively (P<0.05). The positive rate of CEA was 60%, respectively. 40% (P<0.05), suggesting that the higher the positive rate of p53 and CEA expression, the shorter the survival time and the poor prognosis.